MedTech company Cirdan has raised £2.3 million through investment to expand its operations, which is expected to lead to the creation of up to 25 new jobs. The firm’s digital pathology platform, used in over 150 laboratories and hospitals across 20 countries and six continents, collects critical information efficiently and effectively to improve diagnosis time and provide new insights into healthcare data. The platform claims to boost efficiency and agility, provide greater control and visibility, and seamlessly integrate with digital pathology and AI. Cirdan’s rapidly growing revenue is expected to increase by over 80% year on year by 2024.
The investment was led by Kernel Capital through the Bank of Ireland Kernel Capital Growth Fund (NI), with additional participation from Clarendon Fund Managers and high net worth private investors. Cirdan’s director, Stephen Dunniece, expressed his gratitude to investors for their continued support and pledged to use the funds and recent contract wins to accelerate its operational expansion and fulfill its strong order book for 2023 and beyond.
Partner at Kernel Capital, Denise Sidhu, highlighted that Cirdan is a company with a thriving product and a solid team, with “blue-chip” clients across six continents. Capitalizing on the shift from traditional patient care to digital pathology, which could revolutionize disease diagnosis timelines and result in faster and better patient care is the company’s current goal.
It’s a great achievement for the company, and it exemplifies the positive strides the MedTech sector is making.
MedTech company Cirdan has raised £2.3 million through investment to expand its operations, which is expected to lead to the creation of up to 25 new jobs. The firm’s digital pathology platform, used in over 150 laboratories and hospitals across 20 countries and six continents, collects critical information efficiently and effectively to improve diagnosis time and provide new insights into healthcare data. The platform claims to boost efficiency and agility, provide greater control and visibility, and seamlessly integrate with digital pathology and AI. Cirdan’s rapidly growing revenue is expected to increase by over 80% year on year by 2024.
The investment was led by Kernel Capital through the Bank of Ireland Kernel Capital Growth Fund (NI), with additional participation from Clarendon Fund Managers and high net worth private investors. Cirdan’s director, Stephen Dunniece, expressed his gratitude to investors for their continued support and pledged to use the funds and recent contract wins to accelerate its operational expansion and fulfill its strong order book for 2023 and beyond.
Partner at Kernel Capital, Denise Sidhu, highlighted that Cirdan is a company with a thriving product and a solid team, with “blue-chip” clients across six continents. Capitalizing on the shift from traditional patient care to digital pathology, which could revolutionize disease diagnosis timelines and result in faster and better patient care is the company’s current goal.
It’s a great achievement for the company, and it exemplifies the positive strides the MedTech sector is making.
